Illumina Q2 revenue falls 3% to $1.06 billion; raises 2025 non-GAAP EPS outlook
Illumina reported second-quarter 2025 revenue of $1.06 billion, down 3% from a year earlier on both reported and constant currency bases, while GAAP diluted EPS was $1.49 versus a loss of $12.48 a year earlier. The company raised its full-year 2025 non-GAAP diluted EPS guidance to $4.45 to $4.55 and agreed to acquire SomaLogic from Standard BioTools, a deal expected to close in the first half of 2026.
Key points
- Q2 2025 revenue of $1.06 billion, down 3% from Q2 2024 on a reported and constant currency basis
- GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025; non-GAAP operating margin of 23.8%
- FY2025 non-GAAP diluted EPS guidance raised to $4.45 to $4.55, up from $4.20 to $4.30, including about 10 cents from recently passed U.S. R&D tax legislation
- Repurchased about 4.5 million shares for $380 million in Q2; about $800 million authorization remaining at quarter end
The filing
Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.